MNKD (MannKind Corp.) Prakiraan pendapatan perusahaan

Tandha merek Afrezza (MNKD)

A steady stream of royalties from pulmonary hypertension treatments triggered a rally that confirms the expected sales volume of MannKind Corporation (MNKD). The 0.41 level captures the asset's current state. The business relies on partnerships in inhalation technologies, while demand for life-saving therapy guarantees crisis resilience and an absence of seasonal fluctuations.

MNKD - Prakiraan volume dodolan MannKind Corporation ing rentang 04.07.2022 - 17.11.2026

Afrezza (MNKD) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
Analisis komprehensif perusahaan:MannKind Corp
Produk mawa merek MannKind Corp.

For MannKind Corporation (MNKD), whose growth is driven by Tyvaso DPI royalties and the development of an orphan pipeline, the company's projected sales chart serves as an indicator of operational resilience. Through daily recalculations, this metric transforms static data into a dynamic flow, measuring the business's ability to generate profit and preserve capital, which allows investors to filter out market noise from the long-term fundamental trend.

Pesaing utama

Prakiraan volume dodolan HLN|KVUE (Kenvue Inc) - Pendapatan mangsa ngarep perusahaan|Verona Pharma Corp - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan MENS (Jyong Biotech Ltd)|ligand.com - Prakiraan volume dodolan|amneal.com (AMRX) - Volume dodolan mangsa ngarep perusahaan|Perrigo (PRGO) - Prakiraan pendapatan perusahaan|ALVO (Alvotech S.A.) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan LQDA|Prakiraan volume dodolan Galapagos Corp|Prakiraan pendapatan perusahaan ANI Pharma (ANIP)|Prakiraan volume dodolan amphastar.com (AMPH)|Prakiraan volume dodolan PCRX (pacira.com)|Pendapatan mangsa ngarep perusahaan SPRY|Theravance Biopharma Inc - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan Aquestive Therapeutics AQST|SCPH: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Tectonic Therapeutic, Inc.|TNXP (tonixpharma.com) - Prakiraan volume dodolan|SXTC (China SXT Pharmaceuticals, Inc.) - Prakiraan volume pendapatan perusahaan|Prakiraan pendapatan perusahaan eupraxiapharma.com (EPRX)|Prakiraan volume pendapatan perusahaan BHST|Prakiraan pendapatan perusahaan eXoZymes EXOZ|Pendapatan mangsa ngarep perusahaan ORMP|ENTX - Prakiraan pendapatan perusahaan|HYFT: Prakiraan pendapatan perusahaan|ABVC BioPharma, Inc (ABVC) - Prakiraan pendapatan perusahaan|Cumberland Pharma - Pendapatan mangsa ngarep perusahaan|QNTM (Quantum BioPharma Corp) - Prakiraan volume dodolan|FibroGen, Inc. - Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan TELO|Dodolan mangsa ngarep perusahaan Rani Therapeutics Holdings, Inc.|Prakiraan pendapatan perusahaan Synergy CHC Corp. SNYR|Prakiraan volume dodolan rallybio.com RLYB|Lexaria Bioscience Corp. - Prakiraan volume dodolan|PULM: Prakiraan pendapatan perusahaan|PTHL (ftzy.com.cn) - Volume dodolan mangsa ngarep perusahaan|APM: Prakiraan volume pendapatan perusahaan|LYRA (Lyra Therapeutics Inc) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan IBO (Impact BioMedical)|Volume dodolan mangsa ngarep perusahaan TNFA (TNF Pharmaceuticals)|Prakiraan volume dodolan cbdMD Corp (YCBD)|Prakiraan volume dodolan PRFX (PainReform)|Dodolan mangsa ngarep perusahaan Auris Medical (CYTO)|LIPO - Prakiraan pendapatan perusahaan|Optinose (OPTN) - Volume dodolan mangsa ngarep perusahaan|Pieris (PIRS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan PROC (Procaps Group S.A.)|Volume dodolan mangsa ngarep perusahaan PTPI|QLI: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan acelyrin.com (SLRN)|TFFP (TFF Pharma) - Pendapatan mangsa ngarep perusahaan